Prothena Corporation plc Ordinary Shares (PRTA)

About PRTA

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an inve…

Sector

Health Care

Industry

Biotechnology: Pharmaceutical Preparations

Employees

67

Website

www.prothena.com/

Fundamentals

1-day range

$8.91$9.33

Market cap

$449.19M

P/E (trailing)

—

P/E (forward)

-6.11

EPS (trailing)

$-0.83

Dividend yield

—

Beta

-0.33

Avg. volume

548.4K

Forecasts

5 analyst ratings

Prothena Corporation plc Ordinary Shares Competitors

Chosen by industry and closest market cap.

• PRTA

  Prothena Corporation plc Ordinary Shares

  $9.35

  ▲ 2.86%
  Market cap $449.19MP/E —
  $7.73$11.8
• BNTC

  Benitec Biopharma Inc. Common Stock

  $12.51

  ▼ 1.30%
  Market cap $451.07MP/E —
  $9.85$16.76
• LRMR

  Larimar Therapeutics Inc. Common Stock

  $4

  ▼ 1.23%
  Market cap $436.31MP/E —
  $2.72$6.42
• ASMB

  Assembly Biosciences Inc. Common Stock

  $33.97

  ▼ 2.39%
  Market cap $420.36MP/E 333.50
  $20.23$39.71
• QTTB

  Q32 Bio Inc. Common Stock

  $15.01

  ▼ 7.06%
  Market cap $482.18MP/E 15.71
  $1.62$23.57
• PBYI

  Puma Biotechnology Inc Common Stock

  $9.07

  ▼ 1.89%
  Market cap $413.30MP/E 18.65
  $4.3$9.51
• EOLS

  Evolus Inc. Common Stock

  $8.89

  ▲ 0.06%
  Market cap $487.98MP/E —
  $3.86$9.12

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• KMDA or PRTA: Which Is the Better Value Stock Right Now?
  Yahoo · 8/14/2026
• PRTA's Q2 Loss Narrower Than Expected, Pipeline Progress in Focus
  Yahoo · 8/7/2026
• CORRECTION: Prothena Corp Q2 EPS $(0.36) Misses $(0.09) Estimate, Sales $1.010M Miss $28.295M Estimate
  benzinga · 8/7/2026
• CORRECTION: Prothena Corp Q2 EPS $(0.36) Misses $(0.09) Estimate, Sales $1.010M Miss $28.295M Estimate
  Benzinga · 8/7/2026
• Prothena (NASDAQ:PRTA) Beats EPS but Misses Revenue in Mixed Q2 2026 Results
  ChartMill · 8/7/2026
• Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
  Yahoo · 8/6/2026
• Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
  Yahoo · 8/6/2026
• Vanda Pharmaceuticals (VNDA) Reports Q2 Loss, Lags Revenue Estimates
  Yahoo · 8/5/2026

• Anne Evans Kingston · July 29, 2026 · Sale

  7.7K @ $8.47
• Michael John Isaacs · July 29, 2026 · Sale

  8.4K @ $8.47
• Wagner M. Zago · July 28, 2026 · Option Exercise

  51.0K
• Wagner M. Zago · July 28, 2026 · Disposition

  51.0K @ $8.56
• Karin L. Walker · July 28, 2026 · Option Exercise

  15.0K
• Karin L. Walker · July 28, 2026 · Disposition

  15.0K @ $8.56
• Chad J. Swanson · July 28, 2026 · Option Exercise

  51.0K
• Chad J. Swanson · July 28, 2026 · Tax Withholding

  3.5K @ $8.56
• Chad J. Swanson · July 28, 2026 · Disposition

  40.8K @ $8.56
• Brandon S. Smith · July 28, 2026 · Option Exercise

  78.0K
• Brandon S. Smith · July 28, 2026 · Disposition

  78.0K @ $8.56
• Gene G. Kinney · July 28, 2026 · Option Exercise

  84.0K
• Gene G. Kinney · July 28, 2026 · Disposition

  84.0K @ $8.56
• Anne Evans Kingston · July 28, 2026 · Tax Withholding

  3.5K @ $8.56
• Michael John Isaacs · July 28, 2026 · Tax Withholding

  4.7K @ $8.56